Jan 31, 2019 - Skyworks (SWKS) is benefiting from its portfolio strength, particularly in the 5G applications and IoT market.
Jan 30, 2019 -
Jan 30, 2019 - Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Jan 29, 2019 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jan 28, 2019 - Fisher’s 13F portfolio value decreased from $82.37B to $73.22B in Q4 2018.Visa Inc., Amazon.com, Apple Inc., Microsoft, and Pfizer are the largest five individual stock positions.Fisher has substantia
Jan 28, 2019 - Gossamer Bio is a clinical-stage biopharmaceutical company testing treatments in disease areas of immunology, inflammation, and oncology.The most appealing of this name is that it has diverse research
Jan 27, 2019 - Bristol-Myers Squibb reported a solid Q4 and pretty good guidance for 2019, but revenue growth is slowing.In that context and given poor new drug development the last few years, it makes sense for BMS
Jan 27, 2019 -
Jan 26, 2019 -
Jan 25, 2019 - BMO Capital Markets issues rating change for MRK